 Jacquelyn Bainbridge
Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticonvulsants | 6 | 2020 | 217 | 1.570 |
Why?
| | Parkinson Disease | 11 | 2024 | 493 | 1.170 |
Why?
| | Seizures | 5 | 2017 | 426 | 0.710 |
Why?
| | Multiple Sclerosis | 2 | 2016 | 455 | 0.600 |
Why?
| | Drug Resistant Epilepsy | 1 | 2020 | 102 | 0.600 |
Why?
| | Education, Pharmacy | 2 | 2017 | 120 | 0.550 |
Why?
| | Pharmacy | 1 | 2017 | 32 | 0.540 |
Why?
| | Quality of Life | 3 | 2020 | 2892 | 0.530 |
Why?
| | Psychotropic Drugs | 1 | 2016 | 68 | 0.490 |
Why?
| | Neurology | 1 | 2017 | 113 | 0.490 |
Why?
| | Antiparkinson Agents | 3 | 2017 | 27 | 0.470 |
Why?
| | Disability Evaluation | 1 | 2016 | 290 | 0.440 |
Why?
| | Laboratory Proficiency Testing | 1 | 2014 | 10 | 0.440 |
Why?
| | Monitoring, Immunologic | 1 | 2014 | 25 | 0.440 |
Why?
| | CD3 Complex | 1 | 2014 | 106 | 0.430 |
Why?
| | Epilepsy | 4 | 2020 | 333 | 0.430 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 269 | 0.420 |
Why?
| | Creatine | 4 | 2017 | 57 | 0.410 |
Why?
| | Laboratories | 1 | 2014 | 113 | 0.410 |
Why?
| | Immunophenotyping | 1 | 2014 | 318 | 0.400 |
Why?
| | 4-Aminopyridine | 1 | 2012 | 24 | 0.400 |
Why?
| | Potassium Channel Blockers | 1 | 2012 | 37 | 0.400 |
Why?
| | Gait Disorders, Neurologic | 1 | 2012 | 46 | 0.380 |
Why?
| | Cannabidiol | 2 | 2024 | 119 | 0.360 |
Why?
| | Immunotherapy | 1 | 2016 | 641 | 0.360 |
Why?
| | Dronabinol | 3 | 2024 | 226 | 0.350 |
Why?
| | Drug Interactions | 5 | 2016 | 410 | 0.320 |
Why?
| | Piracetam | 1 | 2009 | 13 | 0.320 |
Why?
| | Gait | 1 | 2012 | 296 | 0.320 |
Why?
| | Fructose | 2 | 2008 | 112 | 0.310 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1050 | 0.310 |
Why?
| | Restless Legs Syndrome | 3 | 2016 | 21 | 0.310 |
Why?
| | Monoamine Oxidase Inhibitors | 1 | 2008 | 17 | 0.300 |
Why?
| | Monoamine Oxidase | 1 | 2008 | 30 | 0.290 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 1091 | 0.280 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2014 | 900 | 0.280 |
Why?
| | Walking | 1 | 2012 | 529 | 0.280 |
Why?
| | Epistaxis | 1 | 2006 | 12 | 0.260 |
Why?
| | Caffeine | 2 | 2017 | 68 | 0.240 |
Why?
| | Diabetic Neuropathies | 1 | 2006 | 94 | 0.240 |
Why?
| | Patient Compliance | 1 | 2009 | 581 | 0.220 |
Why?
| | Depression | 3 | 2009 | 1397 | 0.210 |
Why?
| | Disease Progression | 4 | 2017 | 2757 | 0.180 |
Why?
| | Pain | 1 | 2006 | 756 | 0.170 |
Why?
| | Humans | 30 | 2024 | 137585 | 0.170 |
Why?
| | Volatilization | 1 | 2019 | 56 | 0.160 |
Why?
| | Dopamine Agonists | 2 | 2016 | 39 | 0.160 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 86 | 0.160 |
Why?
| | HIV Infections | 1 | 2014 | 2836 | 0.160 |
Why?
| | Ketosis | 1 | 1999 | 12 | 0.160 |
Why?
| | Starvation | 1 | 1999 | 22 | 0.160 |
Why?
| | Pharmaceutical Services | 1 | 1999 | 83 | 0.150 |
Why?
| | Cannabis | 2 | 2023 | 494 | 0.150 |
Why?
| | Comorbidity | 2 | 2016 | 1622 | 0.140 |
Why?
| | Dibenzazepines | 1 | 2017 | 5 | 0.140 |
Why?
| | Severity of Illness Index | 5 | 2017 | 2828 | 0.140 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 47 | 0.140 |
Why?
| | Double-Blind Method | 5 | 2024 | 1993 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1587 | 0.130 |
Why?
| | Metabolic Diseases | 1 | 2017 | 108 | 0.130 |
Why?
| | Teratogens | 1 | 2015 | 10 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 316 | 0.120 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2015 | 33 | 0.120 |
Why?
| | Female | 18 | 2024 | 73304 | 0.120 |
Why?
| | Cognition | 1 | 2023 | 1153 | 0.120 |
Why?
| | Drug Synergism | 1 | 2016 | 382 | 0.120 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2017 | 219 | 0.120 |
Why?
| | Pharmacists | 1 | 2017 | 265 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2024 | 10811 | 0.110 |
Why?
| | Psychiatry | 1 | 2017 | 180 | 0.110 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 275 | 0.110 |
Why?
| | Quality Control | 1 | 2014 | 172 | 0.110 |
Why?
| | Electrocardiography | 1 | 2017 | 629 | 0.110 |
Why?
| | Male | 14 | 2024 | 67762 | 0.110 |
Why?
| | Lactation | 1 | 2014 | 181 | 0.100 |
Why?
| | Observer Variation | 1 | 2014 | 343 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1236 | 0.100 |
Why?
| | Heart Rate | 1 | 2017 | 822 | 0.100 |
Why?
| | Physical Therapy Modalities | 1 | 2016 | 308 | 0.100 |
Why?
| | Computer Simulation | 1 | 2017 | 978 | 0.100 |
Why?
| | Workflow | 1 | 2014 | 165 | 0.100 |
Why?
| | Specimen Handling | 1 | 2014 | 183 | 0.100 |
Why?
| | Data Interpretation, Statistical | 1 | 2014 | 363 | 0.100 |
Why?
| | Program Development | 1 | 2014 | 364 | 0.090 |
Why?
| | Drug Costs | 1 | 2012 | 106 | 0.090 |
Why?
| | Quality Indicators, Health Care | 1 | 2014 | 307 | 0.090 |
Why?
| | Aged | 9 | 2024 | 23961 | 0.090 |
Why?
| | Purines | 1 | 2012 | 176 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2015 | 7635 | 0.090 |
Why?
| | Curriculum | 1 | 2017 | 992 | 0.080 |
Why?
| | Flow Cytometry | 1 | 2014 | 1178 | 0.080 |
Why?
| | Middle Aged | 12 | 2024 | 33479 | 0.080 |
Why?
| | Models, Statistical | 1 | 2014 | 669 | 0.080 |
Why?
| | Program Evaluation | 1 | 2014 | 898 | 0.080 |
Why?
| | Guideline Adherence | 1 | 2014 | 556 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 2014 | 527 | 0.080 |
Why?
| | Epilepsies, Partial | 1 | 2009 | 50 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2031 | 0.070 |
Why?
| | Patient Selection | 1 | 2012 | 696 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 423 | 0.070 |
Why?
| | Recovery of Function | 1 | 2012 | 653 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3284 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2426 | 0.070 |
Why?
| | Citalopram | 1 | 2008 | 29 | 0.070 |
Why?
| | Polypharmacy | 1 | 2009 | 85 | 0.070 |
Why?
| | Memory Disorders | 1 | 2009 | 164 | 0.070 |
Why?
| | Mental Disorders | 1 | 2016 | 1077 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4030 | 0.070 |
Why?
| | Health Services | 1 | 2008 | 107 | 0.070 |
Why?
| | Time Factors | 2 | 2017 | 6828 | 0.070 |
Why?
| | Accreditation | 1 | 2007 | 83 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2007 | 45 | 0.070 |
Why?
| | Risk Assessment | 1 | 2016 | 3457 | 0.060 |
Why?
| | Pharmacy Service, Hospital | 1 | 2007 | 90 | 0.060 |
Why?
| | Quality Improvement | 1 | 2014 | 1178 | 0.060 |
Why?
| | Neoplasms | 1 | 2020 | 2671 | 0.060 |
Why?
| | Longitudinal Studies | 3 | 2017 | 2844 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 408 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1066 | 0.060 |
Why?
| | Data Collection | 1 | 2008 | 673 | 0.060 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5131 | 0.060 |
Why?
| | Adult | 7 | 2017 | 37929 | 0.060 |
Why?
| | Physician-Patient Relations | 1 | 2009 | 548 | 0.050 |
Why?
| | Patient Education as Topic | 1 | 2009 | 766 | 0.050 |
Why?
| | Chronic Disease | 1 | 2009 | 1793 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2057 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4149 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 786 | 0.050 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 85 | 0.040 |
Why?
| | Food-Drug Interactions | 1 | 1999 | 9 | 0.040 |
Why?
| | Diet, Protein-Restricted | 1 | 1999 | 11 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 146 | 0.040 |
Why?
| | Clinical Competence | 1 | 2007 | 1118 | 0.040 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 180 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 413 | 0.040 |
Why?
| | Dietary Carbohydrates | 1 | 1999 | 155 | 0.040 |
Why?
| | Risk Factors | 1 | 2012 | 10388 | 0.040 |
Why?
| | Catechol O-Methyltransferase Inhibitors | 1 | 1997 | 3 | 0.040 |
Why?
| | Cannabinoids | 1 | 2019 | 161 | 0.030 |
Why?
| | Dietary Fats | 1 | 1999 | 304 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 370 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 184 | 0.030 |
Why?
| | Autonomic Nervous System | 1 | 2017 | 75 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2019 | 532 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2019 | 252 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2017 | 192 | 0.030 |
Why?
| | Women | 1 | 2015 | 50 | 0.030 |
Why?
| | Hemodiafiltration | 1 | 1995 | 9 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 1995 | 29 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1997 | 840 | 0.030 |
Why?
| | Palliative Care | 1 | 2020 | 758 | 0.030 |
Why?
| | Central Nervous System Stimulants | 1 | 2015 | 161 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 683 | 0.020 |
Why?
| | Adenosine A2 Receptor Antagonists | 1 | 2012 | 9 | 0.020 |
Why?
| | Counseling | 1 | 2015 | 391 | 0.020 |
Why?
| | Pregnancy | 2 | 2015 | 6763 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2012 | 118 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1916 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 740 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1483 | 0.020 |
Why?
| | Animals | 1 | 2012 | 36940 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2015 | 762 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2012 | 331 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3295 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2189 | 0.020 |
Why?
| | Exercise Test | 1 | 2012 | 625 | 0.020 |
Why?
| | Periodicity | 1 | 2008 | 58 | 0.020 |
Why?
| | Headache | 1 | 2008 | 147 | 0.020 |
Why?
| | Recurrence | 1 | 2008 | 1060 | 0.010 |
Why?
| | Pilot Projects | 1 | 2008 | 1710 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 13209 | 0.010 |
Why?
| | Ergolines | 1 | 1997 | 3 | 0.010 |
Why?
| | Catechols | 1 | 1997 | 14 | 0.010 |
Why?
| | Benzophenones | 1 | 1997 | 16 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2015 | 15657 | 0.010 |
Why?
| | Benzothiazoles | 1 | 1997 | 33 | 0.010 |
Why?
| | Nitrophenols | 1 | 1997 | 34 | 0.010 |
Why?
| | Thiazoles | 1 | 1997 | 123 | 0.010 |
Why?
| | Colorado | 1 | 2007 | 4565 | 0.010 |
Why?
| | Receptors, Dopamine D2 | 1 | 1997 | 97 | 0.010 |
Why?
| | Nitriles | 1 | 1997 | 172 | 0.010 |
Why?
| | Adolescent | 1 | 2015 | 21513 | 0.010 |
Why?
| | Liver Failure | 1 | 1995 | 94 | 0.010 |
Why?
| | Indoles | 1 | 1997 | 412 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1995 | 597 | 0.010 |
Why?
| | Critical Illness | 1 | 1995 | 811 | 0.000 |
Why?
| | Acute Kidney Injury | 1 | 1995 | 815 | 0.000 |
Why?
| | Prospective Studies | 1 | 1995 | 7604 | 0.000 |
Why?
|
|
Bainbridge's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|